Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Sets Feb. 5 Date for Avastin’s Colon Cancer sBLA
FDAnews Drug Daily Bulletin
Oct. 26, 2012 | Vol. 9 No. 211
FDA Sets Feb. 5 Date for Avastin’s Colon Cancer sBLA
The FDA has granted a priority review to Genentech’s sBLA for Avastin in people with metastatic colorectal cancer (mCRC) who have already been treated with chemotherapy plus Avastin. The agency aims to finish its review by Feb. 5. Genentech’s filing is based on a first-of-its-kind prospective Phase III study that evaluated continually inhibiting vascular endothelial growth factor as a potential treatment strategy for mCRC, the Roche subsidiary said Oct. 16.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.